
    
      Methods: In a randomized, double-blind, crossover study, the subjects were treated for 3
      weeks with 1 tablet per night of 2 mg prolonged-release melatonin or placebo, with one week
      washout period in between. Sleep was objectively monitored by wrist actigraphy. Fasting
      glucose, fructosamine, insulin, C-peptide, triglycerides, cholesterol (total, HDL and LDL)
      and some antioxidants were assessed at baseline and end of each period.
    
  